Multidrug-resistant Gram-negative bacteria: Difference between revisions
From IDWiki
No edit summary |
mNo edit summary |
||
| Line 1: | Line 1: | ||
== Background == |
== Background == |
||
| − | * Defined by the European CDC |
+ | * Defined by the European CDC[[CiteRef::magiorakos2012mu]] as non-susceptibility to at least one agent in three or more categories of antimicrobials, with the categories varying by organism |
* Refer to to [[Multidrug-resistant organism|multidrug-resistant organisms]] for specific |
* Refer to to [[Multidrug-resistant organism|multidrug-resistant organisms]] for specific |
||
Latest revision as of 13:08, 27 September 2024
Background
- Defined by the European CDC1 as non-susceptibility to at least one agent in three or more categories of antimicrobials, with the categories varying by organism
- Refer to to multidrug-resistant organisms for specific
Management
- Ceftolozane-tazobactam (Zerbaxa)
- May be better for multidrug-resistance Pseudomonas (or at least more experience with it)
- Ceftazidime-avibactam: available through Special Access Program
- Adds coverage of some carbapenemases and AmpC
- Fosfomycin
- Colistin
- Cefiderocol: available through Special Access Program as well as preapproval by manufacturer
- Meropenem-vaborbactam: still awaiting Health Canada Drug Review
- Imipenem-relebactam (really imipenem-cilastatin-relebactam): still awaiting Health Canada Drug Review
References
- ^ A.-P. Magiorakos, A. Srinivasan, R.B. Carey, Y. Carmeli, M.E. Falagas, C.G. Giske, S. Harbarth, J.F. Hindler, G. Kahlmeter, B. Olsson-Liljequist, D.L. Paterson, L.B. Rice, J. Stelling, M.J. Struelens, A. Vatopoulos, J.T. Weber, D.L. Monnet. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clinical Microbiology and Infection. 2012;18(3):268-281. doi:10.1111/j.1469-0691.2011.03570.x.
